Table 2.

Overall Survival.

		Kaplan-Meier			Cox UVA			Cox MVA
		OS2 (%)	95%CI (%)	p	HR	95%CI	p (class)	HR	95%CI	p (class)	p (variable)
Diabetes/Metformin Category	D + M	73.4	64.7–80.3	< 0.01	.	.	.	.	.	.	0.11
	nD	65.6	62.8–68.3	.	1.37	0.96–1.96	0.08	1.13	0.78–1.65	0.53	.
	DnM	57.7	52.5–62.5	.	1.79	1.23–2.60	< 0.01	1.36	0.92–2.00	0.12	.
Age	66–69	72.5	67.8–76.6	< 0.01	.	.	.	.	.	.	< 0.01
	70–74	73.6	69.3–77.4	.	0.96	0.74–1.24	0.75	1.06	0.82–1.38	0.65	.
	75+	55.0	51.5–58.4	.	1.87	1.51–2.32	< 0.01	2.06	1.64–2.59	< 0.01	.
Sex	Male	66.0	62.9–68.9	0.13	.	.	.	.	.	.	0.43
	Female	62.2	58.4–65.7	.	1.13	0.96–1.33	0.13	1.08	0.90–1.29	0.43	.
Race/Ethnicity	White Non-Hispanic	65.1	62.5–67.6	0.30	.	.	.	.	.	.	0.40
	Non-White or Hispanic	61.6	56.1–66.6	.	1.11	0.91–1.35	0.30	0.91	0.73–1.13	0.40	.
Marital Status	Married	72.7	69.3–75.7	< 0.01	.	.	.	.	.	.	< 0.01
	Non-Married	57.4	54.1–60.6	.	1.74	1.47–2.06	< 0.01	1.43	1.19–1.72	< 0.01	.
Geographic Region	West	64.0	60.4–67.4	0.40	.	.	.	.	.	.	0.48
	East	66.1	60.2–71.3	.	0.94	0.74–1.19	0.63	0.81	0.62–1.07	0.14	.
	Midwest	68.8	62.0–74.6	.	0.86	0.66–1.13	0.29	0.88	0.64–1.21	0.43	.
	South	61.9	57.3–66.2	.	1.08	0.89–1.32	0.41	0.88	0.70–1.11	0.28	.
Population Density	Metropolitan	64.8	62.2–67.4	0.35	.	.	.	.	.	.	0.67
	Non-Metropolitan	62.8	57.4–67.6	.	1.10	0.90–1.33	0.36	0.95	0.75–1.20	0.67	.
Year of Diagnosis	2008	62.8	57.8–67.5	0.64	.	.	.	.	.	.	0.37
	2009	64.0	59.0–68.5	.	0.95	0.75–1.20	0.67	0.94	0.74–1.19	0.60	.
	2010	63.7	58.7–68.2	.	0.97	0.77–1.22	0.79	1.00	0.79–1.26	0.97	.
	2011	66.6	62.2–70.6	.	0.87	0.69–1.09	0.23	0.83	0.66–1.05	0.12	.
Primary Site	Oral Cavity	68.1	64.9–71.2	< 0.01	.	.	.	.	.	.	0.06
	Oropharynx	62.4	58.3–66.2	.	1.24	1.04–1.49	0.02	0.75	0.60–0.95	0.02	.
	Other	55.8	49.0–61.9	.	1.54	1.23–1.94	< 0.01	0.87	0.67–1.13	0.29	.
T-Classification	T0–1	80.3	76.4–83.6	< 0.01	.	.	.	.	.	.	< 0.01
	T2	64.0	59.6–68.1	.	2.00	1.55–2.57	< 0.01	2.00	1.10–3.64	0.02	.
	T3–4	47.3	42.7–51.8	.	3.48	2.74–4.42	< 0.01	5.67	3.21–10.0	< 0.01	.
	Unknown	67.4	60.8–73.2	.	1.88	1.38–2.55	< 0.01	4.31	2.22–8.37	< 0.01	.
N-Classification	N0	71.8	68.7–74.6	< 0.01	.	.	.	.	.	.	< 0.01
	N1	56.2	50.2–61.8	.	1.72	1.39–2.14	< 0.01	1.58	1.24–2.01	< 0.01	.
	N2–3	54.7	50.0–59.2	.	1.80	1.50–2.17	< 0.01	1.78	1.42–2.25	< 0.01	.
Comorbidity Index	0	70.5	67.6–73.2	< 0.01	.	.	.	.	.	.	< 0.01
	1+	54.0	50.0–57.9	.	1.80	1.53–2.12	< 0.01	1.69	1.42–2.01	< 0.01	.
Tract % High School Only	≤ Median	66.8	63.5–69.9	0.02	.	.	.	.	.	.	0.02
	> Median	62.0	58.6–65.2	.	1.21	1.02–1.42	0.02	1.29	1.05–1.59	0.02	.
Tract % Below Poverty	≤ Median	68.2	64.9–71.3	< 0.01	.	.	.	.	.	.	0.45
	> Median	60.6	57.2–63.8	.	1.32	1.12–1.55	< 0.01	1.08	0.89–1.30	0.45	.
Teaching Hospital	No or Unknown	61.1	57.5–64.5	0.01	.	.	.	.	.	.	0.02
	Yes	67.1	64.0–70.1	.	0.80	0.68–0.95	0.01	0.81	0.68–0.96	0.02	.
Surgery	No	51.9	48.0–55.6	< 0.01	.	.	.	.	.	.	< 0.01
	Yes	73.1	70.2–75.7	.	0.48	0.40–0.56	< 0.01	0.54	0.43–0.67	< 0.01	.
Chemotherapy	No	69.0	65.8–71.9	< 0.01	.	.	.	.	.	.	0.35
	Yes	58.9	55.2–62.3	.	1.40	1.19–1.64	< 0.01	0.90	0.72–1.12	0.35	.
Radiotherapy	No	74.2	70.5–77.6	< 0.01	.	.	.	.	.	.	< 0.01
	Yes	59.1	56.1–62.0	.	1.70	1.41–2.04	< 0.01	0.43	0.28–0.65	< 0.01	.
ACEi or ARB	No	61.2	58.2–64.0	< 0.01	.	.	.	.	.	.	0.51
	Yes	70.4	66.5–73.9	.	0.73	0.61–0.88	< 0.01	1.13	0.78–1.65	0.51	.
Statin	No	60.3	57.3–63.2	< 0.01	.	.	.	.	.	.	0.01
	Yes	71.8	68.0–75.3	.	0.66	0.55–0.79	< 0.01	0.75	0.62–0.93	0.01	.
HTN/CKD	No	67.8	62.9–72.1	0.07	.	.	.	.	.	.	0.15
	Yes	63.3	60.6–65.9	.	1.20	0.98–1.46	0.07	1.18	0.94–1.48	0.15	.
HLD	No	58.7	54.5–62.7	< 0.01	.	.	.	.	.	.	0.05
	Yes	67.2	64.4–69.9	.	0.75	0.63–0.88	< 0.01	0.82	0.68–1.00	0.05	.

Abbreviations: OS2, 2-year overall survival; 95%CI, 95% confidence interval; HR, hazard ratio; UVA, univariate analysis; MVA, multivariate analysis; nD, non-diabetic; DnM, diabetic not taking metformin; D + M diabetic taking metformin; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotension II receptor blocker; HTN, hypertension; CKD, chronic kidney disease; HLD, hyperlipidemia.